At a glance
- Originator Shire Pharmaceuticals Group
- Class Antivirals
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cytomegalovirus infections; Influenza virus infections
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 15 Feb 2001 Profile reviewed but no significant changes made
- 14 Jul 1998 No-Development-Reported for Cytomegalovirus infections in Canada (Unknown route)